Perilymph fistulae are difficult to diagn ose because they present with a wide variety of signs and symptoms, they are associated with many etiologies, and they of ten mimic other conditions. In this articl e, we describ e a case of perilymphfistula that f eatured one of its more rare causes: acoustic trauma-specifically, dama ge from a loud bla st from the siren ofafire engine. We also review the literature and discuss the difficult ies ofdiagno sis and treatm ent and the possible mechanisms by which acou stic trauma and other etiologies cause perilymph fis tulae.
a bla st from the siren of a fire engine. When the trauma occurred, the patient 's right ear was app roximately 18 inches from the sire n. Thi s type of siren (Q2B; Federal Signal Corp. ; Universit y Park, Ill. ) can produce 140 dB at a distance of 18 inches and 136 dB at 30 inches.
Immediately after the incid ent , the pati ent noted a se nsation of lancinating right ear pain, extremely loud tinnitus, and mild di zziness. The tinn itu s persisted at a high inten sity for approxi ma tely 6 hours after the incident. Thereafter, the inten sity diminished and the patient noticed a right -sided hearing los s. Th e dizziness per sisted as an intermittent, dail y se nsation of unsteadiness without rotary verti go ; this sen sation was exacerbated by head motion and relie ved by avoid anc e of head motion .
Ex amination revealed that the right tympanic membrane wa s mobile and that it had a slightly prominent vas cular strip. There was no spontaneous ny stagmus, and on positi onal testing the patient experienced feelings of unsteadiness without nystagmus or a sensation of rotary vertigo. Findings on the tandem Romberg 's test were equi vocal , with the patient falling backward with his eyes open . With a 512-Hz tuning fork, Rinne 's test wa s positive bil aterall y, and Weber ' s test revealed that the sound was louder on the left side, indicating a right-sided se nsorineural hearing loss. Pneumatic otoscopy of the right ear elicited Hennebert 's sign.
Pure-tone audiometry reve aled an air conduction threshold in the right ear of 55 to 65 dB from 2,000 to 8,000 Hz and 20 to 25 dB from 250 to 1,000 Hz . Threshold s in the left ear were within normal limits, with the ex ception of a 30-dB threshold at 6,000 Hz. Th e patient had no air-b one gap, his speec h reception thre shold s were con sistent with the findin gs on the pure-tone audiog ra m, and his speech di scriminati on score s we re normal.
Electronystagmography (ENG) dete cted a mild leftbeating nystagmu s on positi onal testing with the right ear down , without a se nsation of vertigo. A fistula test in the right ear was po siti ve, with both a mild right-beating ny stagmu s and a sen sati on of vertigo.
A follow -up aud iogram obtained 2 week s later show ed little change in air conduction, bone co nduction, and speech rece ption thre sholds, but the speec h discrimination score had fallen to 88% at 65 dB (it subsequently improved to 96% at 65 dB on the next audiogra m pri or to middl e ear explora tion). Findings o n magnetic reso nance imaging
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NO IS E-INDUC ED PERILYMPH FISTULA of the brain and internal auditory canals were normal. Laboratory testing revealed normal values for the co mplete blood count, thyroid-stimul ating hormone, Lyme titer, fluorescent trep onemal antibody, antinuc lear antibody, Rh fac tor, erythrocy te sedi menta tio n rate, and antibodies to inner ear antige ns. Th e lipid profile showed eleva ted levels of triglycerides, total cho lesterol, and low-den sity lipoprotein choles tero l.
Over the nex t few weeks, the patien t's hearing loss and tinnit us had stabilized but still persisted, and his periods of di zzin ess became more severe. He was sche duled for surgery. In the operating roo m, he received local anesthesia and sedatio n. The malle us and incus were fou nd to be intac t and mobile, and there was no evi de nce of a fistula of the round window d uri ng Valsalva's maneuver. However, so me filmy adhes ions were noted to be draping the stapes suprastructure ove r the prom ont ory, the facia l nerve, and the ova l window ; a fluid collectio n in the foo tplate area was also obv ious. Th e adhes ions were lysed , the mucosa was scraped off the foo tplate, and the area of the an nulus was denuded . A piece of loose areo lar tissue was harvested through a postauricul ar incisio n and used to sea l the ova l window . Gelfoam was ap plied to fill the middl e ear and stabilize the graft.
Postoperatively, the patient's dizziness disappeared fora brief period , but his hearing loss gra dually becam e worse. Even tually, the dizziness also returned , and his clinica l course became complicated. He was taken back to the operating roo m three more times to revise his perilymph fistula repair. Durin g this period , he also developed a rig ht-s ided faci al para lysis secondary to Ramsay Hunt syndrome , and he underwent total facial nerve decom pression to fully restore his fac ial nerve function.
Over time , the patien t's hearing improved but never fully recovered. His balance imp roved and stab ilized, but he co ntinued to experience bouts of dizziness. Vestibular nerve section was offe red to him seve ral times th rou ghout the co urse of trea tme nt, but he re peated ly declin ed . His managemen t was also rend ered more co mp lex by his early decision to seek a per manent disability design ation through legal ac tion and by his add ictio n to prescript ion narcotics ob tained from other physicians.
Discussion
Th e diag nos is of a peri lymph fistula ca n be diffic ult because of its many possib le ca uses and the hig hly variable signs and symptoms that have been associated with the condition.' Th e preferred metho d of es tab lishing a diagn osis is visual inspection during ex plora tory tympanotom y, eve n though findi ngs are often equ ivocal.' During the past few years, efforts have been und ertaken to es tab lish more objective diagnos tic criteria, but co ntroversy persists.U" Volume 85, Numbe r 4
Perilymph fistula first became recognized as a legitimate cli nica l diagnosis aro und the time that stapedectomy surge ry for otosc lerosis was becomi ng popul ar." The most common ca use is otologic surge ry, particularl y stapes surgery.' Th e first repor t of a per ilymph fistula that was not ca use d iatroge nically was publi shed by Fee in 1968. 9 He described the cases of 3 patient s who each experience d tin nitu s, vertigo, and fluctuating hearing loss followi ng head trauma; eac h was fo und to have a leak of per ilymph from the oval window area duri ng ex ploratory tymp anotomy. In 1970, Stroud and Calc aterra repo rted the first cases of spo ntaneous ova l wi ndow perilymph fistulae and hypoth esized that the inciting eve nts were episo des of increased intr acranial pressure. 10 In 197 1, Goodh ill published his we ll-known theory on the pathoph ysiology of spo ntaneo us peri lymph fistulae .II He proposed that fistulae can occur via two possible mechanism s. Th e first is the hydrodynam ic explosive route, in whic h increased intracranial press ure is transmitted to the perilymphatic space through a patent coc hlear aquedu ct or intern al auditory ca nal, ca using a rupture at either the ova l or round window. The seco nd is the aerodynamic implosive route, in which a sudden increase in middl e ear pressur e fro m eithe r the external aud itory ca nal or the eustachian tube ca uses a rup ture of the ova l or round window.
Si nce then , various anato mic studies have bee n performed on tem poral bones, and theories have arise n abo ut the significa nce of microfissures in the otic capsule in the area of the oval window, the round window niche, and the posterior canal ampulla." Moreover, inves tigators have studied the importance of pat hways between the int racran ial cav ity and the inner ear, par ticularly the coc hlea r aqued uct." Yet des pite all this add itio nal work, not many maj or altera tions have bee n made to Goo dhill 's theory, and it is still wide ly cited today.
One of the most important com po ne nts in the diagnosis of a perilymph fistula is the patient' s history. Knowledge of previou s oto logic diseases and surgery, hea d traum a, barotr auma, co nge nital malformation s and syndro mes, bo uts of rec urre nt menin gitis, and other infectious diseases (e.g., syp hilis) is key to the evalua tion of a possible per ilymph fistula.' The patient' s symptoms are important as we ll, but they are not always diagnos tic. Because the oto logic sy mpto ms of a peri lymph fistula are so varia ble, patients are often misdiagnosed as having so me other otolog ic condition, usually Me niere 's disease. "
The variability of sig ns and sympto ms in patients with perilymph fistula has also been widely studied, and the data have been used to help develop diagnostic criteria.S In 1986, Se ltze r and McCabe pub lished the first large ser ies of patient s with perilymp h fistul a.'? They found that 83% of patients with surgically co nfirmed fistul ae had experience d a hearin g loss; the most com mon type
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Ultima te ly, a diag nosis of pe rilymph fistula must be co nfirmed by direct visualization. However, even surgical co nfirmation ca n be co ntroversial because it is so me times diffic ult to see the leak of per ilymph and to prove th at any visua lize d fluid is actually emanating fro m the inn er ear,"
Various meth ods have been prop osed to help iden tify per ilymph fistulae. Th e most wide ly used method is exploratory tympanotomy under microscopic visualization with intraoperati ve measures such as Valsalva's ma neuve r, bilateral jugul ar vei n co mpression, and Trend elenburg 's posi tioning; endoscopes, labeling methods, and rapid Volume 85, Number 4 fluid analysis have all been studie d and, aga in, res ults have bee n variable. l" Some co ntroversy also attends to the treatment of peril ymph fistulae . Th e goa l of surgery is to stabilize hearing and re lieve ves tibular sy mpto ms.' For patient s with idiopath ic peril ymph fistulae, so me gro ups recommend conservative management first-bed rest, head eleva tion, and avoi dance of strenuous activ ity." However, most otologists reco mme nd early surgica l exploratio n and repair wi th vario us materials, such as subcutan eo us areolar tissue, fat, perich ond rium, fasc ia, fibrin glue, and microfibrillar co llage n."
Despit e the paucity of repo rts on noi se-induced perilymph fistulae, we do know that it is possible for a sufficiently loud aco ustic stimulus to ca use enough movem ent of the oval window to ruptu re it. In th eir 1985 case report on perilym ph fistula ca used by loudspeaker noise, Narul a and Marks menti oned that Dahl mann rep orted in 1954 that the minimu m pressur e on the tympan ic memb ran e necessary to ca use visible movement of the stapes at the oval window is 60 mm Hg, whic h correspo nds to a sound level of 84 dB.6The patient in that cas e repor t had been exposed to a so und level of 130 dB , and our patient had bee n ex pose d to approx ima tely 140 dB.
It is no t inconcei vabl e th at our patient 's ongo ing sy mptoms might have been attributable to posttrau mat ic endo ly mphatic hydrops rather than to his initial per ilymph fistula . As me ntioned , the sig ns and sym ptoms of perilymph fistulae and the findings on diagnostic tests all te nd to mimic those see n in patient s with Meni ere ' s disease, and our case was no exceptio n. A peril ymph leak was obvious at the time of our patie nt's first and second surgical procedures, but a fistula co uld not be confirmed duri ng the subse quent operatio ns. Studies by DiBiase and Arriaga, 16McGill and Schu kne cht ,17 and Kem ink and Graham 18provided histopath ologic ev ide nce of en dolymphatic hydrop s in patients with delayed-on set vertigo following noi se-indu ced hearin g loss. In ' a study of soldiers exposed to noise fro m firearms ( 155 to 190 dB ), Ylikoski reported that all of the soldiers who had ex perienced balance prob lems followi ng exposure to noise did so on a de laye d basis (fro m 6 to 29 yr) and th at more than half of these patients reported attacks of ve rtigo accompa nied by tinnitus.'? Finall y, traum a th at is severe enoug h to ca use a peril ymph fistula may be severe enoug h to also ca use de laye d hyd rops that can be very diffic ult to differentiate from a rec urrent fistula.
In co nclusio n, it is important to recogni ze perilymph fistula as a cause of hearing loss and dizzin ess becau se it is potentially cura ble, des pite the co ntroversies over diagnosis and treatmen t. Ad di tional clinica l and basic research sho uld be encouraged to help answer the remai ning ques tions abou t this co mplex entity .
